Martin P - Search Results

1

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R. Noy A, et al. Among authors: martin p. Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6. Blood. 2017. PMID: 28167659 Free PMC article. Clinical Trial.

2

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.

Martin P, Furman RR, Coleman M, Leonard JP. Martin P, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5636s-5642s. doi: 10.1158/1078-0432.CCR-07-1085. Clin Cancer Res. 2007. PMID: 17875800 Review.

3

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.

Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Leonard J, Kaufmann T. Coleman M, et al. Among authors: martin p. Leuk Lymphoma. 2008 Mar;49(3):447-50. doi: 10.1080/10428190701837330. Leuk Lymphoma. 2008. PMID: 18297520

4

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.

Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP. Coleman M, et al. Among authors: martin p. Cancer. 2008 May 15;112(10):2228-32. doi: 10.1002/cncr.23422. Cancer. 2008. PMID: 18338745 Free article. Clinical Trial.

5

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Martin P, et al. Ann Oncol. 2008 Jul;19(7):1327-1330. doi: 10.1093/annonc/mdn045. Epub 2008 Mar 17. Ann Oncol. 2008. PMID: 18349031 Free article.

6

Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.

Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP. Martin P, et al. Semin Hematol. 2008 Apr;45(2):126-32. doi: 10.1053/j.seminhematol.2008.02.007. Semin Hematol. 2008. PMID: 18381108 Review.

7

FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma.

Rutherford SC, Andemariam B, Philips SM, Elstrom RL, Chadburn A, Furman RR, Niesvizky R, Martin P, Fahey TJ, Coleman M, Goldsmith SJ, Leonard JP. Rutherford SC, et al. Among authors: martin p. Leuk Lymphoma. 2008 Apr;49(4):719-26. doi: 10.1080/10428190801927387. Leuk Lymphoma. 2008. PMID: 18398739

8

New monoclonal antibodies for non-Hodgkin's lymphoma.

Leonard JP, Martin P, Ruan J, Elstrom R, Barrientos J, Coleman M, Furman RR. Leonard JP, et al. Among authors: martin p. Ann Oncol. 2008 Jun;19 Suppl 4:iv60-2. doi: 10.1093/annonc/mdn199. Ann Oncol. 2008. PMID: 18519407 Free article. Review. No abstract available.

9

Targeted treatment and new agents in diffuse large B-cell lymphoma.

Leonard JP, Martin P, Barrientos J, Elstrom R. Leonard JP, et al. Among authors: martin p. Semin Hematol. 2008 Jul;45(3 Suppl 2):S11-6. doi: 10.1053/j.seminhematol.2008.07.004. Semin Hematol. 2008. PMID: 18760704 Review.

10

Progress in mantle-cell lymphoma.

Martin P, Coleman M, Leonard JP. Martin P, et al. J Clin Oncol. 2009 Feb 1;27(4):481-3. doi: 10.1200/JCO.2008.19.5032. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075257 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,911 results

Search Page